Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced the
appointment of Dr. Neil M. Sussman as Vice-President, Neurologic and
Psychiatric Development of Biovail Technologies, Ltd. The appointment
is effective immediately.
Dr. Sussman brings a wealth of business and academic experience in
the field of neurology and other central nervous system (CNS)
disorders to Biovail.
“We are delighted to have an individual as qualified as Dr.
Sussman join our Medical and Scientific Affairs team,” said Bill
Wells, Biovail’s Chief Executive Officer. “The addition of his
expertise and experience in CNS disorders is an important step in the
implementation of Biovail’s New Strategic Focus.”
Prior to joining Biovail, Dr. Sussman was President of NMSNeuro
Consulting, specializing in therapeutic areas such as dementia, mania,
neuroprotection, multiple sclerosis and Parkinson’s disease. Before
that, Dr. Sussman was Senior Director, CNS Clinical Research of Kyowa
Pharmaceutical, overseeing development-stage products in Parkinson’s
disease. Earlier in his career, Dr. Sussman held positions of
increasing responsibly at Marion Merrell Dow where he worked on the
development of vigabatrin (Sabril); Abbott Laboratories, where he
served as Venture Head, Neurotherapeutics; Bristol-Myers Squibb’s CNS
Clinical Research division; and Forest Laboratories, as Director, CNS
Clinical Development, where he was involved in the development of
escitalopram (Lexapro). He also spent four years as Director, Medical
Affairs with PRA International, a global clinical research (CRO)
organization.
Dr. Sussman received his medical training at New York Medical
College and completed his Neurology Residency at Thomas Jefferson
University in Philadelphia. His post-graduate training includes
Fellowships in Neurology, and Epilepsy and Electroencephalography. He
is certified by the American Board of Psychiatry and Neurology, and
was on the faculty of the Department of Neurology at the University of
Pennsylvania, Medical College of Pennsylvania and Yale University
School of Medicine, and he is a Fellow in the American Academy of
Neurology. Dr. Sussman has co-authored over 30 peer-reviewed original
papers in the area of CNS disorders. His knowledge, energy and
extensive network should facilitate Biovail’s future drug-development
success.
About Biovail Corporation
Biovail Corporation is a specialty pharmaceutical company engaged
in the formulation, clinical testing, registration, manufacture, and
commercialization of pharmaceutical products. The Company is focused
on the development and commercialization of medicines that address
unmet medical needs in niche specialty central nervous system (CNS)
markets. For more information about Biovail, visit the Company’s Web
site at www.biovail.com.
For further information, please contact Nelson F. Isabel at
905-286-3000 or send inquiries to ir@biovail.com.